What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025Blood

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis shows improved tumor genotyping in multiple myeloma, suggesting next-generation sequencing enhances immune profiling.

Integrated whole-exome sequencing identified clinically actionable genomic features in multiple myeloma cases, revealing significant insights into somatic variants.
Next-generation sequencing was performed on tumor samples from patients, demonstrating concordance with traditional FISH results in multiple lesions.
RNA sequencing analysis of peripheral blood mononuclear cells provided detailed immune profiling and correlated with lymphocyte counts.
The findings highlight next-generation sequencing as a robust alternative to FISH for comprehensive molecular diagnostics and immune monitoring.

Meerson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis shows improved tumor genotyping in multiple myeloma, suggesting next-generation sequencing enhances immune profiling.

Integrated whole-exome sequencing identified clinically actionable genomic features in multiple myeloma cases, revealing significant insights into somatic variants.
Next-generation sequencing was performed on tumor samples from patients, demonstrating concordance with traditional FISH results in multiple lesions.
RNA sequencing analysis of peripheral blood mononuclear cells provided detailed immune profiling and correlated with lymphocyte counts.
The findings highlight next-generation sequencing as a robust alternative to FISH for comprehensive molecular diagnostics and immune monitoring.

Meerson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark